You can buy or sell DMAC and other stocks, options, ETFs, and crypto commission-free!
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). Read More The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN. The listed name for DMAC is DiaMedica Therapeutics Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 12, After Hours